
After an extensive feedback process the methodology was enhanced with significant augmentations aimed at increasing the robustness of the Index and brings it in line with current changes to global access to medicine priorities. These enhancements included a separate measurement of performance from commitments and transparency, greater focus on non-communicable diseases, specific coverage of innovations in the sector, more diversified sources of information and a more balanced attention to the scale and scope of the company activities and their size.